Differential Plasma Proteins Identified via iTRAQ-Based Analysis Serve as Diagnostic Markers of Pancreatic Ductal Adenocarcinoma
Table 4
Levels of markers in plasma of CA19-9-negative PDAC patients.
Patient number
CA19-9 (U/mL)
AAT (μg/mL)
RAB2B (pg/mL)
IGFBP2 (pg/mL)
1
2.13
2959.17
920.63
5755.00
2
2.55
2642.50
637.29
6680.00
3
2.30
3009.17
745.63
7538.33
4
2.90
3588.33
788.33
6721.67
5
17.90
3130.00
865.42
6255.00
6
13.03
3392.50
900.83
7821.67
7
4.49
4559.17
617.50
9646.67
8
14.67
2656.43
2198.27
6502.50
9
9.61
3117.14
756.92
9352.50
10
19.44
2906.43
941.54
7302.50
11
3.73
1860.00
781.92
5590.00
12
2.00
1667.14
1040.58
6152.50
Marker levels in plasma of CA19-9-negative PDAC patients are shown. The values in bold with asterisks are above the thresholds for AAT, RAB2B, and IGFBP2 presented in Table 3.
